Add on SGLT2 inhibitors to insulin therapy in diabetes patients lowers blood sugar, BP, and weight without reducing eGFR Aditi2 Aug 2023 11:30 AM ISTSGLT2 inhibitors are a class of drugs that lower blood sugar levels by preventing kidneys from reabsorbing sugar that is created by body and the extra...
Dapagliflozin not better than metolazone at relieving congestion in HF patients with loop diuretic resistance Dr. Kamal Kant Kohli19 July 2023 9:15 AM ISTA recent study published in European Heart Journal showed a randomized trial comparing the sodium-glucose cotransporter 2 (SGLT2) inhibitor...
Novel triple-drug FDC superior to dual combination in type 2 diabetes patients poorly controlled with metformin Medha Baranwal2 Jun 2023 11:30 AM ISTIndia: A recent study has shown a triple-drug fixed-dose combination (FDC) of sitagliptin + dapagliflozin + metformin ER to be superior to dual...
Empagliflozin reduces heart failure events across spectrum of CKD: Analysis of EMPEROR trials Medha Baranwal11 May 2023 10:45 AM ISTUSA: Empagliflozin (Jardiance) consistently reduced heart failure (HF) events across the spectrum of chronic kidney disease (CKD), according to...
SGLT2 inhibitors use lowers cancer risk in patients with diabetes Medha Baranwal7 April 2023 11:30 AM ISTTaiwan: Patients with diabetes who receive sodium-glucose cotransporter-2 (SGLT2) inhibitors are at a significantly lower risk of cancer, a new study...
New Gliflozin in town: FDA approves new SGLT2 inhibitor bexagliflozin for glycemic control in Type 2 diabetes Dr. Kamal Kant Kohli24 Jan 2023 12:30 PM ISTThere is a new Gliflozin soon coming in the market as the USFDA has given its nod to bexagliflozin (Brenzavvy by TheracosBio) for use to improve...
SGLT2 inhibitors exhibit enhanced cardioprotective effect in obese or overweight patients Dr Kartikeya Kohli17 Oct 2022 11:00 AM ISTUSA: The cardioprotective effect associated with sodium-glucose cotransporter-2 inhibitor (SGLT2i) compared with dipeptidyl peptidase-4 inhibitors...
Empagliflozin proves beneficial in acute myocardial infarction: EMMY trial Dr. Kamal Kant Kohli11 Sept 2022 7:30 PM ISTAUSTRIA: Acute myocardial infarction (MI) patients who receive the SGLT2 inhibitor empagliflozin (Jardiance) early after the MI have improved markers...
SGLT2 inhibitors foundational therapy in all HF patients regardless of EF: Pooled analysis of DAPA-HF and DELIVER Dr. Kamal Kant Kohli9 Sept 2022 8:00 PM ISTPrevious studies have shown that the SGLT2 inhibitor dapagliflozin reduces cardiovascular mortality and morbidity in patients with diabetes, chronic...
Preoperative SGLT2 inhibitors increase metabolic acidosis with euglycemia, study finds Aditi9 Sept 2022 9:30 AM ISTJapan: According to a retrospective matched cohort study, using sodium-glucose cotransporter 2 (SGLT2) inhibitor preoperatively is associated with...
Empagliflozin may decrease risk of kidney stones in people with diabetes Dr. Kamal Kant Kohli15 Jun 2022 9:15 AM ISTThe diabetes drug empagliflozin may decrease the risk of kidney stones in patients with type 2 diabetes, according to a new study presented Sunday,...
Triple Combo therapy not likely to benefit heart failure patients with preserved HF: Circulation Medha Baranwal2 Jun 2022 11:00 AM ISTUSA: The combined benefits of an angiotensin receptor-neprilysin inhibitor (ARNI), a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose...
